BC
AKTX

Boxer Capital’s Akari Therapeutics AKTX Stock Holding History

Boxer Capital’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-119
Closed -$1.05M – 28
2017
Q1 		$1.05M Sell
119
-56
-32% -$314K 0.23% 27
2016
Q4 		$985K Hold
175
– – 0.38% 23
2016
Q3 		$1.19M Hold
175
– – 0.53% 24
2016
Q2 		$1.89M Hold
175
– – 1.67% 15
2016
Q1 		$1.96M Hold
175
– – 1.92% 14
2015
Q4 		$2.03M Buy
+175
New +$2.6M 1.75% 10

Other funds holding AKTX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Boxer Capital's AKTX Position: Q2 2017 in Review

Boxer Capital sold out of Akari Therapeutics (AKTX) in Q2 2017, closing a stake of 119 shares — an estimated $1.05M sold.

Boxer Capital first reported a position in AKTX in Q4 2015 and held it in 6 quarters. The position peaked at $2.03M in Q4 2015. 14 funds tracked by Wall St. Rank hold AKTX as of Q2 2017.

  • Boxer Capital reported no remaining Akari Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Boxer Capital sold 119 Akari Therapeutics shares in Q2 2017, an estimated $1.05M.
  • Boxer Capital first reported a position in Akari Therapeutics in Q4 2015 and held it in 6 quarters.
  • Boxer Capital's Akari Therapeutics position peaked at $2.03M in Q4 2015.
  • 14 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2017.

Based on Boxer Capital's 13F filing for Q2 2017, filed 14 Aug 2017.